The next evolution of wearable tech for personalised health.

New wearable technology is under development to help prevent or delay the onset of diabetes – the world’s fastest growing chronic condition.

The device, created by Australian startup Nutromics, operates at the intersection of medical grade sensor technology, data science and healthcare.

With one in two adults in the US and China alone at risk of diabetes or diabetic, Nutromics’ innovation is set to empower large populations around the world to take charge of their own health.

The device analyses individuals’ key biomarkers via their skin. Combined with an artificial intelligence coaching engine, and mobile app, real time biofeedback and personalised health recommendations can be made.

Armed with easy to understand insights into how their body responds to aspects of their daily life, such as diet, activity, stress and sleep, individuals will be able to make choices that are better informed than ever to prevent or delay the onset of diabetes. This knowledge is crucial in tackling the world’s diabetes epidemic because there is a long latency period leading up to the disease and during that time, individuals experience few or no symptoms.

Nutromics Co-Founders Hitesh Mehta and Peter Vranes joined the MedTech Actuator’s first cohort in 2018 to learn more about how to navigate the MedTech space and bring a product to market.

The 15-month, industry-led, venture capital backed program for early stage MedTech startups accelerates technology development, builds team capability and provides an initial capital injection plus a pathway to access further investment. The MedTech ActuatorTM works alongside venture capital partner Artesian to support startups in the program.

As a result of the program, Hitesh and Peter have connected with partners Procept, Design + Industry and investor CP Ventures. They’ve pivoted technology to land on their final approach and built a collaborative ecosystem.

“It was beneficial to have the structured framework where we met regularly, learned from our cohort and experts, and applied that back into our startup,” says Hitesh.

“I would definitely recommend the program to anyone who is looking at a MedTech or HealthTech startup in Australia. If you want to get a good, firm understanding of the regulatory pathways to bring a product to market as well as how you engage with key opinion leaders, clinicians and hospitals in the medical community, the program is very relevant.”

The biggest challenge for Hitesh and Peter has been developing their new technology platform, due to its very deep and complex technology integration. They are working through this by collaborating widely and seeking out key experts.

“This collaboration is really the key for other MedTech startups. It is a long road – and it is not as quick as for startups in other areas like FinTech, so you have to be patient,” says Hitesh.

“You’ve also got to think about the fact that you can’t possibly do everything in-house – you’ve got to reach out and co-create and build an ecosystem of end user representatives, payers, partners and experts who can help you on your journey.”

To learn more about Nutromics and follow them on their journey, go to www.nutromics.com.au.

Do you have a MedTech prototype to change lives? Apply now for the MedTech Actuator™ Apply Now

MedTech Actuator™ startup Data Dissect signs MOU with CQInsights Inc.

MedTech Actuator™ startup Data Dissect has signed a Memorandum of Understanding with CQInsights Inc, the US-based global frontrunner in the development and implementation of learning health care systems.

Data Dissect makes it possible for clinicians and health researchers to gather detailed information specific to any health condition in a fraction of the time and resources, when compared to current data collection processes.

Managing Partner of CQInsights, Dr Bruce Ramshaw is a world expert in learning health care systems and an advocate for patient-centred medicine.

“We are excited to collaborate with Data Dissect as it allows us to expand our value-based continuous quality improvement model in Australia,” says Dr Ramshaw.

“We have learned that the problem of improving patient outcomes and costs is not unique to the United States. It is a global problem.”

This exciting development allows Australian clinicians and researchers to access the years of experience and expertise that Dr Ramshaw and his partners, Remi Forman and Briana Alvoid-Preston, bring to this pivotal collaboration.

Data Dissect will gain further insight into the use of learning health care systems to improve the patient journey through the hospital systems – an area that Dr Ramshaw has been at the forefront of for many years.

The Adelaide company’s vision is for this collaboration to promote the benefits of value-based clinical quality improvement to healthcare institutions and clinical teams around Australia.

Importantly, the collaboration will enable an amalgamation of resources from each company to provide insights such as data visualisation and analysis for Australian healthcare institutions and clinical teams.

“Data Dissect is pleased to bring the insights and expertise of Dr Bruce Ramshaw to Australian clinicians. Bruce is a leading figure in the learning health care system community and his contribution to the development of this field in Australia is timely,” says Chairman of Data Dissect, Professor Peter Hewett.